Figure 1.
Schematic representation of the new liposomal/origami technology for the drug delivery of doxorubicin. (a) Liposomal short tube DNA origami (LSTDO) decreases the adverse effect of STDO on mouse liver derived organoids. (b) LSTDO-doxo increases the antitumor effect of doxorubicin on mice bearing breast cancer tumor cells.